Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models

Figure 5 Inhibition of molecular targets in meningioma cell lines (HKB-MM) with GO-Y030 in vitro. A: Hematoxylin and eosin (HE) stains of HKBMM treated with DMSO alone (control); B: Immunohistochemistry (IHC) of the N-Cad in the control of HKBMM; C: IHC of the hepatocellular growth factor (HGF) in the control of HKBMM; D: IHC of NF-kB in the control of HKBMM; E: HE stains of HKBMM treated with GO-Y030 at IC₅₀ × 2; F: IHC of the N-Cad in HKBMM treated with GO-Y030 at IC₅₀ × 2; G: IHC of NF-kB in HKBMM treated with GO-Y030 at IC₅₀ × 2; H: IHC of the HGF in HKBMM treated with GO-Y030 at IC₅₀ × 2; I: The percentage of normal appearance cells in HKBMM treated with GO-Y030 at IC₅₀ × 2; J: The percentage of positive cells for N-Cad in HKBMM treated with GO-Y030 at IC₅₀ × 2; K: The percentage of positive cells for NF-Kb in HKBMM treated with GO-Y030 at IC₅₀ × 2; L: The percentage of positive cells for HGF in HKBMM treated with GO-Y030 at IC₅₀ × 2.